IsoRay Has Nearly 85% Upside, Maxim Analyst Says; PT Lifted To $5
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a Buy rating on IsoRay, Inc. (ISR) and increased his price target to $5.00 (from $3.50), which is driven by his product model and the associated assumptions for market share penetration in prostate cancer, other cancers, and glioma across both products, Proxcelan and GliaSite RTS.
“IsoRay announced the first implant brachytherapy seed (Proxcelan Cs-131) in brain cancer. Cesium-131 emits a high energy level for a short period of time. We find it to be superior to I-125 or Pd-103. Over time, we expect these attributes to drive a 20% market share penetration in the global radiation (localized therapy) $300M marketplace. We continue to be excited for the market share build–account by account and country by country–in both products (seeds and liquid) over the coming year as KOLs convert to Cs-131 based on its superior attributes”, Kolbert wrote.
According to TipRanks.com, which measures analysts and bloggers success rate based on how their calls perform, analyst Jason Kolbert currently has a one-year average return of 6.7% and an 54% success rate. Kolbert is ranked #705 out of 3217 analysts.